Diagnostic Value of Folate Receptor-positive Circulating Tumor Cell in Lung Cancer：A Pilot Study
10.3779/j.issn.1009-3419.2016.12.03
- VernacularTitle:应用FR靶向PCR法检测CTC在肺癌诊断中的临床价值：初步研究
- Author:
LIAN HUANHUAN
1
;
DING ZHIDAN
;
YUAN DONGFENG
;
MA JIE
;
QIN JIANJUN
Author Information
1. 河南省肿瘤医院胸外科
- Keywords:
Folate receptor;
circulating tumor cell;
Targeted PCR;
Auxiliary diagnosis;
Postoperative monitor
- From:
Chinese Journal of Lung Cancer
2016;19(12):813-820
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective The aim of this study is to determine the effcacy and feasibility of a novel folate receptor (FR)-based circulating tumor cell (CTC) detection method in the diagnosis of lung cancer. CTCs were col-lected from 3 mL of blood based on negative enrichment by immunomagnetic beads and then labeled by a conjugate of a tumor-speciifc ligand folate and an oligonucleotide.Methods Atfer washing off redundant conjugates, the bound conjugates were removed and analyzed by quantitative polymerase chain reaction.Results The CTC levels of 97 patients with lung cancer were signiifcantly higher than that of the controls (18 patients with benign lung diseases;P<0.001). With a threshold of 8.7 Folate units, the method showed a sensitivity of 82.5% and a speciifcity of 72.2% in the diagnosis of lung cancer, especially a sensitivity of 86.8% in stage I disease. Compared with the existing clinical biomarkers such as neuron-speciifc enolase (NSE), carcinoembryonic antigen (CEA), and CYFAR21-1, the method showed the highest diagnostic effciency in lung cancer (area under the curve, 0.859; 95%CI: 0.779-0.939) and stage I lung cancer (area under the curve, 0.912; 95%CI: 0.829-0.994). For future work, the CTC levels of 5 lung cancer patients higher than 8.7 Folate units/3 mL in their postoperation.Conclusion FR-positive CTCs were feasible diagnostic biomarkers in patients with lung cancer, as well as in early-stage tumors.
